Salmonson Re-elected To Chair EMA's CHMP
This article was originally published in SRA
Executive Summary
Dr Tomas Salmonson has been re-elected to chair the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for a second three-year term1.
You may also be interested in...
New CHMP Chair Sought As Salmonson’s Tenure At Key EMA Panel Ends
Tomas Salmonson, the longstanding chair of the European Medicines Agency's key scientific committee, the CHMP, is being replaced. The Swedish regulator has held the post for six years, the maximum time allowed.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.